Following the announcement of a €4m funding, Mobidiag Ltd., an Espoo, Finland-based molecular diagnostics company, received a €1.5m loan from Business Finland (formerly Tekes).
The company will use the funds for the development of a sepsis assay on the new Novodiag® system.
Established in 2000 and led by Tuomas Tenkanen, CEO, Mobidiag develops and commercializes innovative solutions to advance the diagnosis of infectious diseases. Via its Amplidiag and Novodiag solutions, the company offers a comprehensive line of products for diagnostics for infectious diseases and antibiotic resistances.
Mobidiag also has subsidiaries in France, UK and Sweden and R&D centers in Finland and France.
FinSMEs
29/05/2018